Silica Microsphere Vaginal Compositions for Sustained Drug Release

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Topical pharmaceutical products often cause skin or mucosal irritation due to ingredients like retinoids, hydroquinone, benzoyl peroxide, and 5-fluorouracil, leading to symptoms such as itching, burning, and inflammation, and existing formulations do not adequately address these issues.

Innovation Solution

Pharmaceutical compositions incorporating silica microspheres impregnated with active ingredients, such as steroids, antibiotics, or antifungals, provide sustained release and reduce irritation by forming a smooth, easy-to-spread formulation that minimizes direct contact with the skin.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional topical formulations containing active ingredients (retinoids, hydroquinone, benzoyl peroxide, 5-fluorouracil) are used, then therapeutic efficacy is achieved, but skin irritation and inflammation occur

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidskin irritation

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

Silica microspheres serve as an intermediary carrier that separates the active ingredient from direct skin contact. The microspheres are impregnated with active ingredients and applied topically, releasing the medication slowly over time while minimizing direct irritation to the skin. This mediator approach allows therapeutic efficacy to be maintained while reducing the harmful irritation effects of conventional formulations.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the physical state and delivery parameters of the active ingredients by incorporating them into silica microsphere carriers. This transformation from conventional liquid or cream formulations to microsphere-based sustained release systems modifies the release rate, concentration profile, and contact characteristics, thereby reducing skin irritation while maintaining therapeutic effect.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If higher concentrations of active ingredients are used to ensure efficacy, then therapeutic effect is enhanced, but skin irritation and adverse reactions increase

Engineering Contradiction:

Improvetherapeutic effectVSAvoidadverse reactions

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The silica microsphere formulation provides continuous, sustained release of the active ingredient over an extended period. This continuous action allows lower initial concentrations to be used while maintaining therapeutic efficacy through prolonged release, thereby reducing peak concentration irritation and adverse reactions associated with high-dose conventional formulations.

Inventive Principle:

Principle #20Continuity of useful action

Solution Approach 2:

The active ingredient is pre-impregnated into the silica microsphere structure during manufacturing, creating a controlled release reservoir. This preliminary incorporation ensures that the medication is delivered in a controlled manner over time, preventing the need for high initial concentrations and reducing acute adverse reactions.

Inventive Principle:

Principle #10Preliminary action

3Speed

If conventional topical products are applied directly to the skin, then immediate effect is achieved, but irritation and inflammation occur

Engineering Contradiction:

Improveimmediate effectVSAvoidirritation

Core Design Contradiction:

SpeedVSObject-affected harmful factors

Solution Approach 1:

The formulation transitions from static, immediate release to dynamic, controlled release. The silica microspheres are designed to release the active ingredient progressively over time, adapting the delivery rate to minimize skin irritation while maintaining therapeutic effect. This dynamic release profile allows the product to provide immediate initial action followed by sustained, gentler delivery.

Inventive Principle:

Principle #15Dynamics

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The compositions offer reduced skin irritation and inflammation by controlled release of active ingredients, maintaining efficacy while enhancing user comfort and reducing adverse reactions.

Implementation Method 1

the active ingredient impregnated in the silica microspheres provides sustained release of the active ingredient

Methodology Applied

Scientific EffectDiffusion: Diffusion

Implementation Method 2

silica microspheres, formed prior to contact with the active ingredient, impregnated with the active ingredient

Methodology Applied

Scientific EffectAdsorption: Adsorption

Data Source

PatentUSRE50804E1Pharmaceutical compositions comprising silica microspheres

Publication Date: 2026.02.24 SOL GEL TECHNOLOGIES LTD

AI summary

Topical vaginal compositions are disclosed herein which include silica microspheres and an active ingredient in the amount of 0.001 to 15.0% w/w selected from estradiol, metronidazole, clindamycin, butoconazole, and combinations thereof. The topical compositions provide sustained release of the active ingredient so as to reduce skin irritation.